Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-ZOTAC: Neoadjuvant TAC +/- Zoledronic Acid in Breast Cancer
NCT01099436Phase 3Completed
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Apr 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Pathologic Complete Response. Started Apr 2010; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01099436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01099436.